Marc Olivier Perret is founder and managing partner of Gilde Healthcare. Marc Olivier joined Gilde in 2000 following a 17 year career at Novartis (initially Ciba-Geigy) during which he gained operational and international experience in business development, restructuring, as country division head and ultimately as M&A Head of one of Novartis’ divisions.
His track record includes a $ 1 billion acquisition of a Merck & Co division, direct involvement in the $11 billion merger and listing of Switzerland-based Syngenta, and several smaller biotechnology deals.
He is co-responsible for general management and supervises the personnel, legal and back-office operations of the Gilde Healthcare franchise.
Marc Olivier Perret is an engineer from École Centrale de Lyon and received an M.B.A. from the HEC Group/Stanford Graduate School of Business.
He is a French national and speaks English, Italian and Spanish. Marc Olivier led investments in Conatus Pharmaceuticals (listed at NASDAQ), Innate Pharma (listed at Euronext) and Neuro3D (acquired by Evotec). He represented Gilde on the boards of CropDesign (sold to BASF), Conatus Pharmaceuticals, Neuro3d and Innate Pharma.